Nordicus Partners Corporation Acquires the Remaining 5% Shares In Orocidin A/S
Nordicus Partners (OTCQB: NORD) has announced the acquisition of the remaining 5% shares in Orocidin A/S, a Denmark-based clinical-stage biopharmaceutical company focused on periodontitis treatment. The transaction involves 200,000 restricted common shares of Nordicus in exchange for the outstanding Orocidin shares, making Orocidin a 100% wholly-owned subsidiary of Nordicus. The deal strengthens Nordicus's position in facilitating Nordic and U.S. life sciences companies' establishment in the U.S. market.
Nordicus Partners (OTCQB: NORD) ha annunciato l'acquisizione del restante 5% delle azioni di Orocidin A/S, un'azienda biofarmaceutica in fase clinica con sede in Danimarca, focalizzata sul trattamento della parodontite. La transazione prevede 200.000 azioni comuni vincolate di Nordicus in cambio delle azioni emesse di Orocidin, rendendo Orocidin una filiale interamente controllata al 100% da Nordicus. L'accordo rafforza la posizione di Nordicus nel facilitare l'istituzione di aziende di scienze della vita nordiche e statunitensi nel mercato americano.
Nordicus Partners (OTCQB: NORD) ha anunciado la adquisición del 5% restante de las acciones en Orocidin A/S, una empresa biofarmacéutica en fase clínica con sede en Dinamarca, centrada en el tratamiento de la periodontitis. La transacción implica 200,000 acciones comunes restringidas de Nordicus a cambio de las acciones en circulación de Orocidin, convirtiendo a Orocidin en una subsidiaria totalmente propiedad de Nordicus. El acuerdo refuerza la posición de Nordicus en facilitar el establecimiento de empresas de ciencias de la vida nórdicas y estadounidenses en el mercado de EE. UU.
Nordicus Partners (OTCQB: NORD)은 덴마크에 본사를 둔 임상 단계의 생명공학 회사인 Orocidin A/S의 남은 5% 주식을 인수했다고 발표했습니다. 이 거래는 Orocidin의 미발행 주식에 대한 대가로 Nordicus의 제한된 보통주 200,000주를 포함하며, Orocidin은 Nordicus의 100% 자회사로 전환됩니다. 이번 거래는 Nordicus가 북유럽 및 미국 생명과학 기업들이 미국 시장에 진출하는 데 도움을 주는 데 있어 입지를 강화합니다.
Nordicus Partners (OTCQB: NORD) a annoncé l'acquisition des 5 % restants des actions de Orocidin A/S, une entreprise biopharmaceutique danoise en phase clinique spécialisée dans le traitement de la parondite. La transaction concerne 200 000 actions ordinaires restreintes de Nordicus en échange des actions en circulation d'Orocidin, faisant d'Orocidin une filiale entièrement détenue à 100 % par Nordicus. Cet accord renforce la position de Nordicus pour aider les entreprises nordiques et américaines des sciences de la vie à s'établir sur le marché américain.
Nordicus Partners (OTCQB: NORD) hat die Übernahme der verbleibenden 5% der Anteile an Orocidin A/S, einem dänischen biopharmazeutischen Unternehmen in der klinischen Phase mit Schwerpunkt auf der Behandlung von Parodontitis, bekannt gegeben. Die Transaktion umfasst 200.000 eingeschränkte Stammaktien von Nordicus im Austausch für die ausstehenden Orocidin-Aktien, wodurch Orocidin eine 100%ige Tochtergesellschaft von Nordicus wird. Der Deal stärkt die Position von Nordicus, nordeuropäischen und US-amerikanischen Lebenswissenschaften Unternehmen den Markteintritt in den USA zu erleichtern.
- Complete ownership (100%) acquired of Orocidin A/S, strengthening corporate control
- All-stock transaction preserves cash resources
- Share dilution due to issuance of 200,000 new restricted common shares
Beverly Hills, California., Nov. 12, 2024 (GLOBE NEWSWIRE) -- Nordicus Partners Corporation (OTCQB: NORD) (“Nordicus” or the “Company”), a financial consulting company specializing in providing Nordic and U.S. life sciences companies with optimal conditions to establish themselves on the U.S. market, today announced it has entered into an agreement with Orocidin A/S (“Orocidin”) to acquire the remaining approximately
Upon closing of the acquisition, Orocidin became a
About Orocidin A/S
Orocidin A/S, a Denmark-based clinical-stage biopharmaceutical company, is aiming to revolutionize the treatment of aggressive periodontitis, making it safer, more effective, and efficient to prevent and cure those who are affected by periodontitis. For more information about Orocidin, please visit: www.orocidin.com
About Nordicus Partners Corporation
Nordicus Partners Corporation specializes in providing Nordic and U.S. life sciences companies with the best possible conditions to establish themselves on the U.S. market, taking advantage of management’s combined +90 years of experience in the corporate sector, serving in different capacities both domestically and globally. Nordicus’ core competencies lie in assisting Danish as well as other Nordic and U.S. companies in different areas of corporate finance activities, such as: business- and market development, growth strategies, attracting the right people, partners and capital for businesses and company acquisitions and sales. In May 2024 Nordicus bought
Forward-Looking Statements
The Company believes that this press release contains forward-looking statements as that term is defined in the Private Securities Litigation Reform Act of 1995. Terms such as “may,” “might,” “would,” “should,” “could,” “project,” “estimate,” “pro-forma,” “predict,” “potential,” “strategy,” “anticipate,” “attempt,” “develop,” “plan,” “help,” “believe,” “continue,” “intend,” “expect,” “future,” and terms of similar import (including the negative of any of these terms) may identify forward-looking statements. Such forward-looking statements, including but not limited to statements regarding the plans and objectives of management for future operations, are based on management’s current expectations and are subject to risks and uncertainties that could cause results to differ materially from the forward-looking statements. Actual results and the timing of certain events and circumstances may differ materially from those described by the forward-looking statements as a result of these risks and uncertainties. Factors that may influence or contribute to the accuracy of the forward-looking statements or cause actual results to differ materially from expected or desired results may include, without limitation, market acceptance of the company’s products and services; competition from existing products or new products that may emerge; the implementation of the company’s business model and strategic plans for its business and our products; estimates of the company’s future revenue, expenses, capital requirements and need for financing; current and future government regulations; and developments relating to the company’s competitors. Readers are cautioned not to place undue reliance on forward-looking statements because of the risks and uncertainties related to them. For further information on such risks and uncertainties, you are encouraged to review the Company’s filings with the Securities and Exchange Commission (“SEC”), including its Annual Report on Form 10-K for the fiscal year ended March 31, 2024 and its Quarterly Report on Form 10-Q for the fiscal quarter ended June 30, 2024. The Company assumes no obligation to update any forward-looking statements as a result of new information or future events or developments, except as required by law.
For further information contact
Mr. Henrik Rouf
Chief Executive Officer
Phone +1 310 666.0750
Email hr@nordicuspartners.com
FAQ
What percentage of Orocidin A/S did Nordicus Partners (NORD) acquire in November 2024?
How many shares did Nordicus Partners (NORD) issue for the Orocidin acquisition?
What is Orocidin A/S's main business focus?
